Reservoir targeted vaccine against Borrelia burgdorferi: a new strategy to prevent Lyme disease transmission.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 24523510.
- Also identified by DOI 10.1093/infdis/jiu005 and PMC identifier 4038139.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A high prevalence of infection with Borrelia burgdorferi in ixodid ticks is correlated with a high incidence of Lyme disease. The transmission of B. burgdorferi to humans can be disrupted by targeting 2 key elements in its enzootic cycle: the reservoir host and the tick vector. In a prospective 5-year field trial, we show that oral vaccination of wild white-footed mice resulted in outer surface protein A-specific seropositivity that led to reductions of 23% and 76% in the nymphal infection prevalence in a cumulative, time-dependent manner (2 and 5 years, respectively), whereas the proportion of infected ticks recovered from control plots varied randomly over time. Significant decreases in tick infection prevalence were observed within 3 years of vaccine deployment. Implementation of such a long-term public health measure could substantially reduce the risk of human exposure to Lyme disease.
Medical subject headings
- Borrelia burgdorferi
- Lyme Disease
- Lyme Disease Vaccines
- Vaccination